Biomedical Research and Therapy Logo

Biomedical Research and Therapy

Original Research Open Access Logo

Short-term clinical outcomes in patients with acute myocardial infarction after successful percutaneous coronary revascularization: the role of promoter polymorphism of the endothelial nitric oxide synthase gene

Olga V. Petyunina 1
Mykola P. Kopytsya 1
Denis P. Babichev 2
Alexander E. Berezin 3, *

  1. Department of prevention and treatment of emergency conditions, Government Institution “L.T.Malaya Therapy National Institute NAMSU”, 2A Liubovi Maloy av., 61039, Kharkiv, Ukraine
  2. Department of clinical pharmacology and pharmacogenetic on non-communicable diseases, Government Institution “L.T.Malaya Therapy National Institute NAMSU”, 2A Liubovi Maloy av., 61039, Kharkiv, Ukraine
  3. Therapeutic Unit, Internal Medicine Department, State Medical University of Zaporozhye, 26, Mayakovsky av., Zaporozhye, 69035, Ukraine
Correspondence to: Alexander E. Berezin, Therapeutic Unit, Internal Medicine Department, State Medical University of Zaporozhye, 26, Mayakovsky av., Zaporozhye, 69035, Ukraine. Email: [email protected].
Volume & Issue: Vol. 6 No. 5 (2019) | Page No.: 3166-3179 | DOI: 10.15419/bmrat.v6i5.543
Published: 2019-05-31

Online metrics

Statistics from the website

  • HTML Views: 7028
  • PDF Views: 1965
  • XML Views: 0

Statistics from Dimensions

Statistics from PlumX
Copyright © 2019 by the author(s).

This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Background: The purpose of this study was to investigate the associations between variants of a promoter polymorphism of the endothelial nitric oxide synthase (eNOS) gene and clinical outcomes in acute ST-segment elevation myocardial infarction (STEMI) patients after a successful primary percutaneous coronary artery intervention (PCI).

Methods: 177 patients with acute STEMI, 82 patients with angiographically proven stable coronary artery disease, and healthy volunteers were included in the study. The primary end-point was a combined event (follow-up major adverse cardiac events –MACEs and hospitalization) that occurred within 6-month of the discharge from the hospital.

Results: The combined end-point was determined in 72 patients from the entire acute STEMI population (40.6%), including 24 events for 786TT genotype, 23 events for 786TC genotype and 25 events for 786CC genotype. Kaplan-Meier curves demonstrated that acute STEMI patients with 786CC eNOs genotype had lower MACEs free accumulation when compared to those with 786TC and 786TT eNOs genotypes at 6-month follow up period (Log-rank p < 0.001). Multivariate Cox regression analyses identified 786CC in eNOs gene as an independent predictor of clinical outcomes in STEMI after PCI.

Conclusions: the 786CC polymorphism in eNOs gene is an independent predictor for clinical outcomes after a successful primary PCI in acute STEMI.

 

Keywords: endothelial NO-synthase gene outcomes single nucleotide polymorphism Т786С STEMI

Introduction

Nitric oxide (NO) is an established factor in maintaining endothelial function and vascular wall integrity1,2,3,4. Genetic polymorphisms of endothelial NO synthase (eNOs) is associated with altered NO levels in peripheral blood, increased levels of plasma low-density lipoproteins (LDL) and oxidized lipids, suppressed the production of vascular endothelial growth factor and increased fasting glucose5,6,7 These findings were reported to have clinical significance in acute ST-segment elevation myocardial infarction (STEMI), stable coronary artery disease (CAD), asymptomatic atherosclerosis, heart failure (HF), abdominal obesity, hypertension, diabetes mellitus, and restenosis and thrombosis after primary percutaneous coronary artery intervention (PCI)8,9,10 Previous studies have shown that polymorphism in promoter region of eNOs gene (T786C) in STEMI patients is corresponding with impaired pleiotropic effect of NO, which led to adverse cardiac remodeling, early stent thrombosis and restenosis after PCI 11,12,13,14. T786C eNOs genotype can predict cardiovascular (CV) mortality in high-risk patients15 and individuals with stable CAD16, while several studies have reported controversies issues regarding the discriminative values of T786C eNOs genotype in STEMI patients17,18. There is limited evidence regarding the association of T786C polymorphism in eNOs gene and short-term clinical outcomes in STEMI after completed revascularization19. The study aimed to investigate the associations between SNP Т786С in eNOS gene and clinical outcomes in acute STEMI patients after a successful PCI.

Methods

Patients’ population

A total of 268 patients with confirmed acute STEMI and 82 patients with angiographically proven stable CAD, age- and sex-matched to STEMI individuals, were checked for eligibility to participate in the study (Figure 1). Fifty-five healthy volunteers were included as a healthy control group. From the entire patient population of established acute STEMI (n=268), 177 individuals, who were admitted to intensive care unit of GI “L.T.Malaya TNI NAMSU” within a given period from 2016 August to 2018 July and met inclusion/non-inclusion criteria, were enrolled in the study. Ninety-one patients with acute STEMI were excluded from the study due to incompletion of inclusion/exclusion criteria, including time window frame for performing coronary revascularization procedure. Acute STEMI was diagnosed according to the European Cardiology Society (ECS) Guidelines (2017)20. Inclusion criteria were established for acute STEMI cases of age > 18, who have no contraindications to PCI. Cases with previous myocardial infarction, established chronic heart failure, known malignancy, severe comorbidities (anemia, chronic obstructive lung disease, bronchial asthma, liver cirrhosis, chronic kidney disease, valvular heart disease, bleeding), inability to understand of written informed consent were excluded from the study. Primary PCI with bare-metal stent (COMMANDER, “Alvimedica”, Turkey) implantation was performed. All acute STEMI patients received adjuvant treatment due to current ESC recommendations20.

Figure 1

The flow chart of study design, inclusion / exclusion criteria and study procedures.

Ethical declaration

All procedures performed in this study that involved human participants were in accordance with ethical standards, the 1964 Helsinki declaration and its later amendments, or comparable ethical standards, and were approved by the local ethics committee (Protocol №8, 29.08.2016). Informed consent was obtained from each patient.

Determination of endpoints

The primary end-point was combined events (follow-up major adverse cardiac events –MACEs and hospitalization) that occurred within 6-month after the discharge from the hospital21. MACEs were defined as the composite of CV death, recurrent MI, newly diagnosed HF. CV death was confirmed by personal or phone contact to the family doctor or the hospital where the patient died. The diagnosis of myocardial infarction 20 and heart failure (HF) 22 has been established according to the ESC clinical guidelines. Hospitalization was ascertained by direct or phone contact with the hospital reception, where the patient was admitted.

Sample size calculation

The sample size was calculated through the effect size estimation (0.99), the type of present study, providing study power of 80% and type I error 5%23. The sample size was 150 individuals.

Coronary angiography

Conventional coronary angiography was performed immediately after admission of the patients to the hospital using Digital X-Ray system “Integris Allura” (Philips Healthcare, Best, The Netherlands) and managed by radial vascular access as per conventional protocol. In this study, the contrast “Ultravist-370” (Baier Pharma GmbH, Germany) and automatic contrast injector were used. The coronary arteries were divided into segments according to the American Heart Association classification24.

Determination of STEMI prognosis

TIMI score was used to validate prognostic capacity after STEMI25.

SYNTAX score determination

SYNTAX score (SS) was used to assess the severity of coronary atherosclerotic lesions and was calculated by an experienced interventional cardiologist26.

Determinationof riskfactors and comorbidities

Dyslipidemia was diagnosed according to the ECS dyslipidemia guideline (2016)27. Hypertension was diagnosed if systolic blood pressure (SBP) was >140 mm Hg, and/or diastolic blood pressure (DBP) was >90 mm Hg according to the ECS guideline on diagnostics and treatment of arterial hypertension (2018)28. Type 2 diabetes mellitus (T2DM) was determined according to the new ADA statement (2017)29.

Echo and Doppler examination

Echo-CG was performed on an “Aplio 500” (TUS-A500, TOSHIBA MEDICAL SYSTEMS corporation Japan) using a 3.5 MHz phase probe at discharge and 6-month observation period. LV end diastolic volume (EDV), LV end systolic volume (ESV), and LV EF measurement was performed according to Simpson's biplane method as per the contemporary recommendation of American Society of Echocardiography30. LV global longitudinal strain (e`) and early transmitral velocity (E) were measured by tissue Doppler imaging technique and impulse transmitral Doppler regime at baseline and 6-month follow-up. Left ventricular myocardial mass (LVMM) was calculated automatically based on the protocol of echocardiograms evaluation31.

Blood samples

Blood samples were collected immediately before PCI and at six months of investigation. Blood samples were centrifuged, and serum was isolated within 30 minutes after sample collection. Then, final samples were frozen at -70C and stored in plastic tubes until further examination.

Troponin I (Tn I) level was measured by chemo-luminescent immunoassay (Humalyser 2000, Mannheim, Germany). The TnI level average was 0.5-50 ng/mL.

Total cholesterol (TC), low LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) levels were measured by a direct enzymatic method (Roche P800 analyzer, Basel, Switzerland). The intra-assay and inter-assay coefficient variation was <5%.

Fasting glucose levels were measured by a double-antibody sandwich immunoassay (Elecsys 1010 analyzer, F. Hoffmann-La Roche Diagnostics, Mannheim, Germany). The intra-assay and inter-assay coefficient variation was <5%.

Total creatine kinase (CK) and CK MB-fraction (CK-MB) levels were analyzed using immunoinhibition method on a quantitative immunoassay analyzer Humalyser 2000 (HUMAN GmbH, Germany), according to the manufacturers’ recommendations

N-terminal fragments of brain natriuretic peptide (NT-proBNP) were measured by commercially available standard kit (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). The NT-proBNP level average was 10-12000 pg/mL.

Plasma stable metabolic end products of NO

The blood sample for NO measure was collected before nitroglycerin was given through . or orally. The stable metabolic end products of NO (NOx=NO2 plus NO3) in the supernatants of peripheral blood samples were analyzed by Griess method28. We performed measurement using the commercial “Total Nitric Oxide and Nitrate/Nitrite Parameter Assay” Kit produced by RnD Systems (Minneapolis, MN, USA) and analyzer Immunochem-2100 (High technology, Inc., USA). The level of average was 0.78–200 µmol /L. Analytical sensitivity was 0.78–200 µmol/L.

SNP T786C (rs2070744) in eNOS gene determination

The DNA extraction was performed according to the protocol of a commercial set, DNA-Sorb-B (AmplySens, Russia). The assessment of allelic states of SNP studied was performed using real-time (RT) polymerase chain reaction (PCR). The commercial qPCR mix kit, SNP-Screen (catalog number NP-554-100, Syntol, Russia), was used for RT-PCR.

primer sequences were as follows:

F: 5’-ACCAGGGCATCAAGCTCTTC-3’,

: 5’-GCAGGTCAGCAGAGAGACTAG-3’,

rs2070744-C: 5’-VIC-AGGGTCAGCCGGCCAG-BHQ1-3’, C

rs2070744-T: 5’-FAM-AGGGTCAGCCAGCCAG-BHQ1-3’. T

PCR was performed on a CFX96 thermocycler (BioRad, USA) using an allelic discrimination test. PCR conditions: 95°C – 3', 40 cycles of 95°C – 15'', 65°C – 40''

Statistics

Statistical analyses were performed using SPSS for Windows v.23 (USA). Continuous variables are presented as mean ± standard deviation (SD) when normally distributed, or median and interquartile range (IQR) if otherwise. Categorical variables are presented as frequencies (n) and percentages (%). Differences between groups were assessed using the unpaired two-tailed Student’s t-test or Mann-Whitney U test and the chi-square test for continuous and categorical variables, respectively. Allele frequencies were estimated, and all genetic polymorphisms of eNOs were tested for Hardy–Weinberg Equilibrium. Univariate correlation and linear regression analysis (stepwise) were performed to identify independent risk factors for combined end-point in STEMI patients (MACE + hospitalization). We calculated beta coefficient, standard deviation (SD), odds ratio (OR), and 95% confidence interval (CI) for each factor. Factors, for which P values were calculated as >0.1, were not included in the multivariate log-regression. The multiple continuous dependent variables analysis (MANCOVA) was used to assess statistical differences between multiple continuous variables. Wilk’s λ and partial eta squared (η2) were calculated for each predictor. The Kaplan-Meier method and the log-rank test were used to compare the rates of combined endpoints in STEMI patients with , polymorphisms of eNOs according to 6-month survival rates. Multivariate Cox regression analyses, which were adjusted for SYNTAX score, abdominal obesity, T2DM and dyslipidemia (those variables with a significance level of p <0.05 in a univariate test and clinically considered valuable) were conducted. All differences were considered statistically significant with 2-tailed p<0.05.

Results

The observed frequency of Т786С eNOs genotypes in the population of acute STEMI patients (n=177) was as follows: TT=41.2% (n=73), ТС = 36.1% (n=64) and CC=22.6% (n=40) respectively. Deviation from Hardy–Weinberg equilibrium was noted due to an excess of homozygosity (χ2=6.31, P=0.012). The expected frequency of Т786С eNOs genotypes determined in stable CAD patients (n=82) was as follows: TT=47.6% (n=39); CT=37.8% (n=31); CC=14.6% (n=12). There was no deviation from the Hardy–Weinberg equilibrium (χ2=2.2985, P=0.129). Healthy volunteers (n=55) had TT eNOs genotype in 56.4% (n=31); CT genotype in 32.7% (n=18); and CC genotype in 10.9% (n=6) of cases without significant deviation from expecting frequencies (χ2=1.6844, P=0.194).

Table 1

Characteristics of stable CAD and STEMI patients included in the study

Entire stable CAD population (n=82)

Entire STEMI population (n=177)

STEMI population (n=177)

P value

TT genotype

(n=73)

TC genotype

(n=64)

CC genotype

(n=40)

1

2

3

Age, years (SD)58.60±7.2061.73±9.4459.00±10.1059.27±9.9258.53±8.29
Male, n (%)63 (76.8%)139 (78.5%)57 (78.1%)50 (78.1%)32 (80.0%)
Female, n (%)19 (23.2%)38 (21.5%)16 (21.9%)14 (21.9 %)8 (20.0%)
Hypertension, n (%)59 (71.9%)146 (82.5%)#60 (82.2 %)55 (85.9 %)31 (77.5 %)
T2DM, n (%)19 (23.1%)44 (24.9%)15 (20.5 %)13 (20.3 %)16 (40.0 %) P1-3 =0.027P2-3 =0.029
Smoking, n (%)37 (45.1%)84 (47.5%)29 (39.7 %)31 (48.4 %)24 (60.0 %)P1-3 =0.039
HCE, n (%)44 (53.6%)105 (59.3%)45 (61.6 %)37 (57.8 %)23 (57.5 %)
BMI>30 кг/м2, n (%) 20 (24.4%)69 (39.0%)#29 (39.7 %)26 (40.6 %)14 (35.0 %)
Stable CAD prior to STEMI, n (%)-107 (60.5%)42 (57.5%)39 (60.9 %)26 (65.0 %)
Unstable angina prior to STEMI, n (%) -67 (37.9%)21 (28.8 %)24 (37.5 %)22 (55.0 %)P1-3 =0.011P2-3 =0.080
Peak TnI, ng/mL -17.7 [6.34-77.2]17.97 [9.73-60.5]17.7 [3.87-129.0] 25.05 [3.99-180.0]
Peak CK-MB,U/L -103.3 [44.9-28.95] 108.90 [74.30-328.40] 112.90 [55.00-196.90] 43.85 [30.20-158.50]
NT-proBNP at admission, pg/mL96 [86 - 118]246 [107 - 405]#247 [118 - 388]253 [121 - 375] 241 [105 - 344]
NT-proBNP at discharge, pg/mL89 [82 - 105]121 [88 - 145]117 [92 - 144]119 [90 - 147]123 [93 - 151]
Total cholesterol, mmol / L4.91 [4.12-6.20] 4.82 [3.95-5.63] 4.83 [3.91-5.79] 4.62 [3.95-5.50] 4.89 [3.79-5.58]
HDL-cholesterol, mmol / L1.06 [0.94-1.17] 1.12 [0.92-1.28] 1.12 [0.92-1.28] 1.13 [0.94-1.31] 1.05 [0.90-1.28]
LDL cholesterol, mmol / L3.14 [2.20-4.10] 3.00 [2.03-3.63] 2.64 [1.87-3.46] 2.79 [2.04-3.56] 3.36 [2.46-4.13] P1-3 =0.048
NO(x), micromole/L17.10 [12.50 – 21.40] 25.90 [14.76 – 40.71]#39.55 [21.46 – 50.40]31.67 [20.46 – 43.74]16.43 [10.55 – 22.21] P1-3 =0.012

There were significant differences between stable CAD and acute STEMI patients in frequencies of hypertension, obesity, serum levels of NT-proBNP, and NO(x) (Table 1). All acute STEMI patients were matched to age, sex, arterial hypertension, stable CAD before STEMI developing, hypercholesterolemia, and obesity. Consequently, T2DM, smoking unstable angina before STEMI, premature MI, and previously reported MI were more frequent in patients with 786СС genotype than other individuals. Therefore, all cohorts were comparable in serum concentrations of troponin T, CK-MB, NT-proBNP, total cholesterol, and high-density lipoprotein cholesterol. Additionally, serum levels of LDL cholesterol in patients with CC-genotype were significantly higher than those of other genotypes. Plasma levels of NO(x) were significantly lower in acute STEMI patients with 786СС genotype compared to others, but there was no significant difference in biomarker levels between patients with 786TT and 786TT genotypes.

Table 2

STEMI localization and number of damaged coronary arteries in patients included in the study depending on major / minor alleles at baseline

Entire population n=177

TT genotype

n=73

TC genotype

n=64

CC genotype

n=40

P value

1

2

3

STEMI risk scoring

TIMI risk score, point6 [4-7]6 [5-7] 6 [4-7] 7 [5-8]0.62
SYNTAX score, point28.7±6.1 23.6±4.8 25.8±5.1 31.9±5.4 0.043
>32 points, n (%)76 (42.9)20 (27.4)25 (39.1)31 (77.5)0.042
22 - 32 points, n (%)79 (44.6)42 (57.5)32 (50.0)5 (12.5)0.041
≤22 points, n (%)22 (12.4)11 (15.1)7 (10.9)4 (10.0)0.050
STEMI Localization
Anterior LV wall, n (%)97 (54.8%)44 (60.3 %)33 (51.6 %)20(50.0 %)
Posterior LV wall, n (%)70 (39.5%)29 (39.7 %)31 (48.4 %)20 (50.0 %)

Amount of coronary vessels injured

One artery, n (%)53 (29.9%)24 (32.9 %)18 (33.3 %)11 (33.3 %)
Two and more arteries, n (%)103 (58.2%)45 (61.6 %)36 (66.6 %)22 (66.6 %)
Left anterior descending, n (%) 47 (26.6%)25 (34.2%) 9 (14.1%) 13 (32.5%) P1-3 =0.009P1-3 =0.048
Right coronary artery, n (%) 41 (23.2%)22 (30.1%)12 (18.8%)7 (17.5%)
Circumflex coronary artery, n (%)20 (11.3%)9 (12.3%)6 (9.4%)5 (12.5%)
Left main, n (%)12 (6.8%)7(9.6%) 2 (3.1%)3 (7.5%)P1-3=0.035P1-3=0.05

There were no significant differences between the three cohorts in TIMI risk, STEMI localization, numbers of damaged coronary arteries, and complication of MI. However, damages in the left anterior descending artery were frequent in patients with CC genotype of eNOs gene (Table 2). On the contrary, there were significant differences in SYNTAX score between patients from three cohorts. Indeed, SYNTAX score > 32 points and SYNTAX score equaled 22 - 32 points frequently appeared in CC genotype STEMI patients.

Additionally, left primary damage was more frequent in individuals with TT genotypes than those who had TC genotype, but there was no significant difference in the frequency of the left primary damage among patients with CC, TC and TT genotypes.

Combined end-point was determined in 72 patients from entire acute STEMI population (40.6%), including 24 events occurred in 786TT in eNOs genotype, 23 events were determined in 786TC in eNOs genotype and 25 events were found in 786CC in eNOs genotype. There were no significant differences between patients’ cohorts within in-hospital periods, while heart failure, MACE, hospitalization, and combined endpoint were frequent in STEMI patients with CC genotype (Table 3).

Table 3

Clinical events in acute STEMI patients

Entire population n=177

TT genotype

n=73

TC genotype

n=64

CC genotype

n=40

P value

1

2

3

In-hospital events in STEMI patients

Total quantity of complicated acute STEMI, n (%)69 (38.9%)30 (41.1 %)22 (34.4 %)17 (42.5 %)
II-III Killip class of HF, n (%)28 (15.8%)16 (21.9 %)8 (12.5 %)4 (10.0 %)
IV Killip class of HF, n (%)10 (0.6%)5 (6.8 %)1 (1.6 %)4 (10.0 %)
Cardiac arrest, n (%)3 (1.7%)1 (1.4 %) 02 (5.0 %)
Acute 2-3 grade av-block, n (%) 5 (2.8%)2 (2.7 %)1 (1.6 %)2 (5.0 %)
Recurrent angina, n (%) 1 (0.6%) 1 (1.4 %) 0 0

Six-month events in STEMI patients after discharge from the hospital

Heart failure, n (%) 46 (26.0%)14 (19.2%)17 (26.6%)15 (37.5%)P1-3 =0.033
CV death, n (%) 12 (6.8%)5 (6.8%)4 (6.25%)3 (7.5%)
MACE, n (%) 58 (32.8%)19 (26.0%)21 (32.8%)18 (50.0%)P1-3 =0.038P2-3 =0.040
Hospitalization, n (%) 17 (9.6%)5 (6.8%) 5 (7.8%)7 (17.5%) 1-3 =0.022 2-3 = 0.022
Combined end point, n (%) 72 (40.6%)24 (32.9%)23 (35.9%)25 (62.5%) 1-3 =0.025 2-3 = 0.036

Table 4

Hemodynamics in STEMI patients enrolled in the study

Parameters

TT genotype

n=73

TC genotype

n=64

CC genotype

n=40

P value

At baseline

HR, per min80.81±16,6874.17±14.8477.00±16.64PTT-CC =0.012
SBP, mmHg 138.48±27.13136.70±29.00139.00±27.52
DBP, mmHg 82.14±13.1880.92±12.7280.00±13.88
LV EDV, ml137.60±33.36131.91±45.47149.72±44.63
LV ESV, ml 65.08±23.3460.98±31.2777.32±36.96
LA, cm4.14±0.604.09±0.444.22±0.43
LV EF, % 51.25±8.2354.59±8.9650.84±11.96
Е/А, unit 1.00±0.531.03±0.461.16±0.52
E/e`, unit8.44±1.279.18±1.25 13.90±1.90 PTT-CC =0.026PCT-CC =0.046
LV MM, g266.39±70.88249.63±74.72268.98±93.31

At 6 month

HR, per min68.95±10.0369.78±12.51 68.83±12.18
SBP, mmHg140.00±15.33131.11±15.37 132.29±14.14
DBP, mmHg83.33±10.2985.56±16.85 83.13±10.30
LV EDV, ml140.97±35.84144.42±48.25159.26±56.88
LV ESV, ml65.54±24.1868.07±31.2982.53±48.66
LA, cm4.14±0.514.13±0.594.35±0.66
LV EF, %53.89±8.9553.21±8.8050.75±11.55
Е/А, unit 1.20±0.561.14±0.561.21±0.68
E/e`, unit9.15±1.3311.25±1.21 18.32±2.44 PTT-CC =0.014PcT-CC =0.042
LV MM, g242.30±89.12230.59±71.48265.24±76.45

Hemodynamics in STEMI patients enrolled in the study is reported in Table 4. Apart from HR, E/e` ratio and LV end-diastolic volume, other hemodynamic performances did not differ between patients’ cohorts at baseline. E/e` ratio was the only parameter that significantly differed between patient cohorts at six months.

There were positive correlations between СС genotype and the combined end point (r=0.54; P=0.0001), SYNTAX score (r=0.34; P=0.002), LDL cholesterol (r=0.32; P=0.012), T2DM (r=0.30; P=0.042), abdominal obesity (r=0.28; P=0.016), TIMI score (r=0.26; P=0.012), unstable angina prior to acute STEMI (r=0.25; P=0.047), E/e` ration (r=0.23; P=0.048) and total quantity of complications due to acute STEMI within admission to the hospital (r=0.23; P=0.042). CC genotype was inversely correlated with NO(x) (r=-0.52; P=0.001), LV EF (r=-0.33; P=0.001) and diastolic BP (r=-0.26; P=0.048) in acute STEMI patients at baseline. There were no significant associations between 786СС eNOs gene polymorphism and acute STEMI localization, the levels of circulating biomarkers of acute myocardial injury/necrosis (peak levels of TnI and CK-MB), NT-proBNP at discharge, and the numbers of damaged coronary arteries.

Table 5

The factors contributing 6-month combined end point after STEMI: The results of univariateand multivariate linear regressions

Data

Depending variable: combined end point

Univariate linear regressive analysis

Multivariate linear regressive analysis

β-coefficient

OR

95% CІ

Р

β-coefficient

OR

95% CІ

Р

786СС genotype of eNOS 1.58366 4.8728 1.4093 – 16.8481 0.0123 1.57342 4.82311.5349 – 15.15520.0071
SYNTAX score 1.17560 1.9428 1.2493 – 3.5422 0.0244 1.41380 1.6844 1.183 – 2.3655 0.0234
TIMI score 1.37250 1.8970 0.9720 – 2.880 0.0410 1.17280 1.0940 1.010 – 1.3240 0.0520
Smoking 0.51264 1.6697 0.3756 – 7.4222 0.5006 ----
T2DM 0.35065 0.7042 0.2961 – 1.6748 0.4276 ----
Abdominal obesity1.12320 2.1448 0.4607 – 3.8995 0.0383 1.02 1.95600.0774 – 3.4539 0.0526
II-III Killip class of acute HF before PCI0.14908 0.8615 0.0713 – 4.3338 0.8565 ----
Stable CAD prior to STEMI0.43968 1.5522 0.3988 – 6.0419 0.5260 ----
Unstable angina prior to acute STEMI0.78264 2.3177 1.0611 – 4.1522 0.0462 0.71551 1.2317 0.9815 – 4.1772 0.1622
Multiple coronary vessel injury 0.22359 0.7996 0.1766 – 1.2622 0.3370 ----
E/e` at discharge 0.35360 0.9160 1.0136 – 1.1630 0.0870 ----
LDL cholesterol0.72550 1.4271 0.9388 – 3.229 0.6630 ----
NT-proBNP at discharge1.18440 1.7044 1.0633 – 2.954 0.03420 1.17230 1.0144 1.0330 – 1.1422 0.0620
Peak TnI at admission0.97510 1.1774 1.0814 – 1.302 0.0467 0.9880 1.1034 1.0024 – 1.1852 0.0710
Peak CK-MB at admission0.47640 1.0254 1.0180 – 1.104 0.4820 ----
Dyslipidemia0.45820.88480.6638 – 1.12550.6388----

Table 6

The comparison of statistical difference between predictors for combined end point: The results of the multivariate analysis ofcovariance (MANCOVA)

Predictors

Wilk’s λ

F

Partial η2

Observed power

Intercept0.779.2320.2771.000
786СС genotype of eNOS 0.8112,44*0.3421.000
SYNTAX score > 32 units0.629.65*0.3110.946
TIMI score > 7 units0.576.57*0.2950,766
E/e`>18 unit 0.433.220,230.288
Abdominal obesity0.536.340.580.477
Unstable angina prior to acute STEMI 0.596.110.730.512
NT-proBNP at discharge0.684.250.0720.299
Peak TnI at admission0.774.070.0680.316
Dyslipidemia0.615.380.240.246

Determination of predictors of 6-month end-point

The univariate linear regression (stepwise) analysis has allowed verifying 786СС eNOs genotype, SYNTAX score, TIMI score, abdominal obesity, NT-proBNP and peak TnI at admission and unstable angina before acute STEMI as predictors for meeting combined end-point (Table 5). Multivariate regressive logistic analysis showed that 786СС eNOs genotype remained an independent predictor for combined end-point (β-coefficient=1.57342; odds ration =4.8231; 95% confidence interval = 1.5349 – 15.1552; P=0.0071) (Table 5).

Multivariate analysis of covariance showed that 786СС genotype of eNOS (Wilk’s λ = 0.81; F=12.44; Partial η2 = 0.342), SYNTAX score > 32 units (Wilk’s λ = 0.62; F=9.65; Partial η2 = 0.311) and TIMI score > 7 units (Wilk’s λ = 0.57; F=6.57; Partial η2 = 0.295) had independent power on dependent variables entitled combined end-point (MACE + hospitalization) (Table 6).

Table 7

Predictors for end point accumulation: Results of Unadjusted and Adjusted Cox regression for SYNTAX score, TIMI score and T2DM

Predictors

Unadjusted Cox regression

Adjusted Cox regression

OR

95% CI

P value

OR

95% CI

P value

786СС eNOs genotype 1.461.16 – 1.890.0031.481.12 – 1.900.002
SYNTAX score >33 units 1.261.13 – 1.440.001---
TIMI score>7 units 1.151.08 – 1.280.001---
Abdominal obesity 1.041.00 – 1.100.4601.021.00 – 1.050.788
T2DM1.181.04 – 1.280.002---
E/e`>18 unit 1.031.00 – 1.070.0541.021.00 – 1.050.784
Unstable angina prior to acute STEMI 1.071.01 – 1.130.0481.000.98 – 1.040.908
NT-proBNP at discharge1.041.02 – 1.090.0461.031.00 – 1.070.606
Peak TnI at admission1.021.00 – 1.050.4261.021.00 – 1.040.776
Dyslipidemia1.010.93 – 1.110.7601.000.96 – 1.060.790

Kaplan-Meier analysis for end-point accumulation trends in STEMI patients with eNOs genotypes

Kaplan-Meier curves demonstrated that acute STEMI patients with 786СС eNOs genotype had a lower MACEs free accumulation when compared to those with 786TC and 786TT eNOs genotypes at six months follow up period (Log-rank p < 0.001) (Figure 2). There was no significant difference between 786TC and 786TT eNOs genotypes in accumulation of combined clinical end-point.

Figure 2

Kaplan-Meier analysis for end point accumulation trends in STEMI patients with different eNOsgenotypes.

Multivariate Cox regression analyses

Multivariate Cox regression analyses, which were adjusted for SYNTAX score, TIMI score, T2DM showed that 786СС eNOs genotype has remained a powerful independent predictor of accumulation of combined end-point in acute STEMI patients after a successful primary PCI for a 6-month out-hospital period (Table 7).

Discussion

The results of our study have demonstrated significant associations between 786CC eNOS polymorphism and short-term clinical outcomes in acute STEMI patients after a successful primary PCI. This is new evidence regarding the discriminative values of 786CC eNOs genotype in accumulation of clinical events, after adjustment for SYNTAX score, TIMI score, and T2DM. Dyslipidemia and lipids in peripheral blood were not the factors contributing to the impact of 786CC eNOS polymorphism on clinical outcomes, even though T2DM was determined as a predictor. Previous clinical studies have shown that several comorbidities (T2DM, dyslipidemia, the severity of atherosclerosis, smoking) were reported as co-factors influenced on natural evolution of acute myocardial infarction13,32. Early investigations were not confirmed as predictive potency of 786СС in eNOs gene polymorphism in acute STEMI patients17,18,as these studies were performed before the primary PCI era. We suggest that the relationship of eNOS gene variants with short-term clinical outcomes in acute STEMI patients could be clinically significant in TIMI III revascularization after primary PCI, but we could not compare the effect of 786СС polymorphism in eNOs gene in TIMI I-II STEMI individuals due to ethical reasons. Because altered NO bioavailability in patients with 786СС polymorphism in eNOs gene can cause endothelial cell dysfunction, restenosis and early thrombosis of the stent33,34, we received a clinical confirmation regarding the independent negative impact of 786СС polymorphism in eNOs gene on MACE and hospital admission after STEMI over 6 months after completed reperfusion. Additionally, this finding can be important for acute STEMI patients with angiographically normal large coronary arteries, because there was evidence that 786СС polymorphism was associated with acute myocardial infarction, especially without severe coronary organic stenosis35,36,37. However, a risk of STEMI-related complications can sufficiently increase in individuals with 786CC polymorphism38,39. Possible molecular mechanisms contributing to unfavorable clinical evolution after TIMI III reperfusion in presenters of 786CC polymorphism in eNOs gene can be restenosis, thrombosis, and heart failure developing due to adverse cardiac remodeling and no-reflow phenomenon. Indeed, we found that diastolic function in patients with 786TC / 786TT polymorphism was better than in individuals with 786CC polymorphism, but global function assayed with LVEF calculation did not differ. Probably, pre-existing severity of atherosclerosis, T2DM, and other metabolic disorders, such as dyslipidemia, influenced the restoring of blood flow after PCI and determined the support of cardiac structure and function. In fact, eNOs gene sequence variations have been reported as crucial factors for CV risk40,41, and in close relation to conventional CV risk factors42,43. Promoter polymorphism of the eNOs gene was reported with tight association with reduced mRNA and protein expression in damaged myocardium and that this altered expression has corresponded to other CV risk factors, which led to declined levels of vasoprotective agents, such as vascular endothelial growth factor44,45. Thus, 786СС polymorphism in eNOs gene accompanied CV risk factors could be used to determine abnormal myocardial perfusion after completed revascularization in acute STEMI patients. Consequently, it is suggested that impaired cardiac function due to microvascular blood flow abnormality could be the main cause that leads to worsening of clinical outcomes over six months after TIMI III reperfusion with PCI in acute STEMI patients with 786СС polymorphism in eNOs gene. The future investigation could be directed to identify the predictive values of 786СС polymorphism in eNOs gene in a larger population of acute STEMI patients with different approaches to reperfusion and various successes in PCI-related blood flow restoring.

Conclusions

In conclusion,786СС polymorphism in eNOs gene may be an independent predictor for MACE and recurrent hospital admission after successful primary PCI in acute STEMI patients.

List of abbreviations

ADA: American Diabetic Association

CAD: coronary artery disease

CI: 95% confidence interval

CK-MB: creatinine kinase isoenzyme-MB

CV: cardiovascular

DBP: diastolic blood pressure

E: early transmitral velocity

e`: global longitudinal LV strain

ECS: European Cardiology Society

EDV: end diastolic volume

EF: ejection fraction

eNOS: endothelial NO synthase

ESV: end systolic volume

HDL: high density lipoprotein

HF: heart failure

IQR: interquartile range

LDL: low density lipoprotein

LV: left ventricular

MACE: major cardiovascular events

MANCOVA: multiple continuous dependent variables analysis

NO: nitric oxide

NT-proBNP: NT-fragment pro-natriuretic peptide

PCI: percutaneous coronary intervention

SBP: systolic blood pressure

SD: standard deviation

STEMI: ST segment elevation myocardial infarction

T2DM: type 2 diabetes mellitus

TC: total cholesterol

TG: triglycerides

Competing Interests

There are no conflicts of interest.

Authors' Contributions

Conception and design: OVP; writing of the article OVP, MPK, and AEB; collection of clinical data: OVP, DPB and MPK; statistical analysis: OVP and AEB; critical revision of the article for intellectual content: AEB; interpretation of the data: OVP, MPK, and AEB; visualization procedures: DPB.

Funding

The study is a fragment of the research project: “To study the biochemical, genetic mechanisms of reperfusion damage of the myocardium and to assess the cardioprotective effect of antiplatelet therapy in acute myocardial infarction”, State Registration No. 0117U003028 / Ukraine.

References

  1. H. Li, S. Horke, U. Förstermann. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014; 237(1): 208-19.
  2. C. Jia, T. Liu, Z. Liu, M. Li, M. Hu. Joint effects of eNOS gene T-786C and ADH2 Arg47His polymorphisms on the risk of premature coronary artery disease. Thromb Res 2007; 120(5): 679-84.
  3. G. Ghilardi, M.L. Biondi, M. DeMonti, M. Bernini, O. Turri, F. Massaro. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. Clin Chem 2002; 48(7): 989-93.
  4. U. Förstermann. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459(6): 923-39.
  5. T. Tsukada, K. Yokoyama, T. Arai, F. Takemoto, S. Hara, A. Yamada. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245(1): 190-3.
  6. Y. Han, W. Xu, W. Zhang, N. Liu, Y. Ji. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology 2010; 85(4): 211-6.
  7. U. Paradossi, E. Ciofini, A. Clerico, N. Botto, A. Biagini, M.G. Colombo. Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298\textemdash>Asp and T-786\textemdash>C polymorphisms. Stroke 2004; 35(6): 1305-9.
  8. C. Fatini, F. Sofi, E. Sticchi, F. Gensini, A.M. Gori, S. Fedi. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am Heart J 2004; 147(3): 516-21.
  9. F. Navarro-López. Genes and coronary heart disease . Rev Esp Cardiol 2002; 5(4): 413-31.
  10. M. Yoshimura, H. Yasue, M. Nakayama, Y. Shimasaki, H. Ogawa, K. Kugiyama. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786\textemdash>C and missense Glu298Asp variants. J Investig Med 2000; 48(5): 367-74.
  11. C. Ciftçi, S. Melil, Y. Cebi, M. Ersöz, P. Cağatay, M. Kiliçgedik. Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease. Lipids Health Dis 2008; 7(1): 5.
  12. A.H. Gomma, M.A. Elrayess, C.J. Knight, E. Hawe, K.M. Fox, S.E. Humphries. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 2002; 23(24): 1955-62.
  13. X.Z. Kong, Z.Y. Zhang, L.H. Wei, R. Li, J. Yu. The Endothelial Nitric Oxide Synthase Gene T-786C Polymorphism Increases Myocardial Infarction Risk: A Meta-Analysis. Med Sci Monit 2017; 23: 759-66.
  14. J.P. Casas, L.E. Bautista, S.E. Humphries, A.D. Hingorani. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109(11): 1359-65.
  15. G.P. Rossi, G. Maiolino, M. Zanchetta, D. Sticchi, L. Pedon, M. Cesari. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol 2006; 48(6): 1166-74.
  16. D. Liu, Z. Jiang, L. Dai, X. Zhang, C. Yan, Y. Han. Association between the - 786T>C 1polymorphism in the promoter region of endothelial nitric oxide synthase (eNOS) and risk of coronary artery disease: a systematic review and meta-analysis. Gene 2014; 545(1): 175-83.
  17. O. Poirier, C. Mao, C. Mallet, V. Nicaud, S.M. Herrmann, A. Evans. Polymorphisms of the endothelial nitric oxide synthase gene - no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 1999; 29(4): 284-90.
  18. . Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
  19. K. Harada, R. Kikuchi, H. Ishii, Y. Shibata, S. Suzuki, A. Tanaka. Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction. Int J Cardiol Heart Vasc 2018; 19: 3-7.
  20. B. Ibanez, S. James, S. Agewall, M.J. Antunes, C. Bucciarelli-Ducci, H. Bueno, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119-77.
  21. K.A. Hicks, J.E. Tcheng, B. Bozkurt, B.R. Chaitman, D.E. Cutlip, A. Farb, American College of Cardiology, American Heart Association. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation 2015; 132(4): 302-61.
  22. P. Ponikowski, A.A. Voors, S.D. Anker, H. Bueno, J.G. Cleland, A.J. Coats, Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18(8): 891-975.
  23. A. Kirby, V. Gebski, A.C. Keech. Determining the sample size in a clinical trial. Med J Aust 2002; 177(5): 256-7.
  24. W.G. Austen, J.E. Edwards, R.L. Frye, G.G. Gensini, V.L. Gott, L.S. Griffith. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51(4): 5-40.
  25. D.A. Morrow, E.M. Antman, A. Charlesworth, R. Cairns, S.A. Murphy, J.A. de Lemos. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102(17): 2031-7.
  26. A.P. Kappetein, K.D. Dawkins, F.W. Mohr, M.C. Morice, M.J. Mack, M.E. Russell. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg 2006; 29(4): 486-91.
  27. A.L. Catapano, I. Graham, G. De Backer, O. Wiklund, M.J. Chapman, H. Drexel, Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-344.
  28. B. Williams, G. Mancia, W. Spiering, E. Agabiti Rosei, M. Azizi, M. Burnier, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
  29. . Standards of medical care in diabetes -2017: summary of revisions. Diabetes Care 2017; 40: 4-5.
  30. R.M. Lang, L.P. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, L. Ernande. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1):
  31. M. Galderisi, M.Y. Henein, J. D'hooge, R. Sicari, L.P. Badano, J.L. Zamorano, European Association of Echocardiography. Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes. Eur J Echocardiogr 2011; 12(5): 339-53.
  32. I. Jo, J. Moon, S. Yoon, H.T. Kim, E. Kim, H.Y. Park. Interaction between -786TC polymorphism in the endothelial nitric oxide synthase gene and smoking for myocardial infarction in Korean population. Clin Chim Acta 2006; 365(1-2): 86-92.
  33. C. Heltianu, G. Costache, A. Gafencu, M. Diaconu, M. Bodeanu, C. Cristea. Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction. J Cell Mol Med 2005; 9(1): 135-42.
  34. J.Y. Chen, Z.X. Ye, X.F. Wang, J. Chang, M.W. Yang, H.H. Zhong. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomed Pharmacother 2018; 97: 423-8.
  35. M. Nakayama, H. Yasue, M. Yoshimura, Y. Shimasaki, H. Ogawa, K. Kugiyama. T(-786)\textemdash> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 2000; 86(6): 628-34.
  36. Z.X. Xu, G.Q. Li. Association between endothelial nitric oxide synthase gene786T/C polymorphism and myocardial infarction in Xinjiang Uygur and Han population. Journal of Chinese Practical Diagnosis and Therapy 2013; 27: 753-5.
  37. A.M. Zigra, L.S. Rallidis, G. Anastasiou, E. Merkouri, A. Gialeraki. eNOS gene variants and the risk of premature myocardial infarction. Dis Markers 2013; 34(6): 431-6.
  38. X.Z. Kong, Z.Y. Zhang, L.H. Wei, R. Li, J. Yu. The Endothelial Nitric Oxide Synthase Gene T-786C Polymorphism Increases Myocardial Infarction Risk: A Meta-Analysis. Med Sci Monit 2017; 23: 759-66.
  39. O.V. Petyunina, M.P. Kopytsya, A.E. Berezin. Biomarker-based Prognostication of Adverse Cardiac Remodeling after STEMI: the Role of Single Nucleotide Polymorphism T786C in Endothelial NO-synthase gene. J Cardiol Ther 2019; 6(1): 768-74.
  40. X.L. Wang, J. Wang. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 2000; 70(4): 241-51.
  41. J.P. Casas, G.L. Cavalleri, L.E. Bautista, L. Smeeth, S.E. Humphries, A.D. Hingorani. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 2006; 164(10): 921-35.
  42. A.S. Arun Kumar, G. Umamaheswaran, R. Padmapriya, J. Balachandar, C. Adithan. Endothelial nitric oxide synthase gene polymorphisms and the risk of acute myocardial infarction in a South Indian population. Mol Biol Rep 2013; 40(2): 1275-81.
  43. J. da Costa Escobar Piccoli, V. Manfredini, F.I. Hamester, J.B. Bandinelli, I.M. Turkienicz, J.A. Chies. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Arch Med Res 2012; 43(3): 205-11.
  44. A.A. Doshi, M.T. Ziolo, H. Wang, E. Burke, A. Lesinski, P. Binkley. A promoter polymorphism of the endothelial nitric oxide synthase gene is associated with reduced mRNA and protein expression in failing human myocardium. J Card Fail 2010; 16(4): 314-9.
  45. S. Wang, J. Lu, Q. You, H. Huang, Y. Chen, K. Liu. The mTOR/AP-1/VEGF signaling pathway regulates vascular endothelial cell growth. Oncotarget 2016; 7(33): 53269-76.

Comments